Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …

The use of targeted biologic therapies for hematological malignancies has greatly expanded
in recent years. These agents act upon specific molecular pathways in order to target …

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western
countries and is characterized by the clonal expansion of mature CD5+ B cells. There have …

Importance Quality of life (QoL) is an important consideration in cancer medicine, especially
because drugs are becoming more costly and may only result in modest gains in overall …

Background Patients with chronic lymphocytic leukaemia and high-risk features have poorer
outcomes on ibrutinib than those without high-risk features. The aim of this study was to …

Opinion statement Treatment landscape of chronic lymphocytic leukemia (CLL) has
changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway …